Skip to content

Grace Therapeutics, Inc.

GRCE· NasdaqCore metricsCIK 1444192

Pharmaceutical preparations551 peers

Last sale
Nov 12, 2026 · -3.99%
Market cap
$37.97M
21.04M shares
Filings
598
$100.00M
FY 2022+50,920.4% FY22 yoy
-$2.13M
Q2 2027N/M FY26 yoy
-$2.29M
Q2 2027N/M FY26 yoy
-$4.35M
Q1 2021derivedN/M FY19 yoy
-$0.11
Q2 2027N/M FY26 yoy
$21.31M
Q2 2027−23.3% FY26 yoy
$37.97M
—
—
0.7×
—
—

FY2026 figures · derived

Price

$1.8140.03%$1.20past year
Nov 12, 2026 · IEX last sale
Figure
Range
IEX last saleClose of recordAs traded

Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

Financials

Revenue

$100.00MFY 2022
$100.00M0FY 2021FY 2022
PeriodEndedValueKindSource trail
FY 20222022-03-31$100,000,000 revisedreported
FY 20212021-03-31$196,000reported

Pharmaceutical preparations

Grace Therapeutics, Inc. is the 345th largest of the 552 covered companies the SEC files under this code, by market cap. SIC 2834

Peers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in market cap first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.

Grace Therapeutics, Inc. · CIK 1444192 · Engraved from SEC EDGAR